A multicenter, multinational study to assess the safety and efficacy of antithrombin alfa [ATryn] in hereditary antithrombin (AT) deficient patients in high-risk situations for thrombosis.

Trial Profile

A multicenter, multinational study to assess the safety and efficacy of antithrombin alfa [ATryn] in hereditary antithrombin (AT) deficient patients in high-risk situations for thrombosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2013

At a glance

  • Drugs Antithrombin alfa (Primary)
  • Indications Deep vein thrombosis; Thromboembolism; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Sponsors rEVO Biologics
  • Most Recent Events

    • 15 Feb 2013 Retrospective study analysis of two pivotal phase 3 studies presented at the February 2013 meeting of the Society for Maternal-Fetal Medicine (SMFM), according to a rEVO Biologics media release.
    • 15 Jul 2011 Planned end date changed from 1 Aug 2007 to 1 Jul 2008 as reported by ClinicalTrials.gov.
    • 28 Feb 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top